Breast cancer patients who may benefit from therapy regimens using FASN inhibitors, which may have highly toxic effects on HER2-overexpress breast cancers, could be recognized by the overexpression of HER2 of the tumor. This evidence concerns the gene FASN and breast carcinoma.